Noninvasive blood tests to guide personalized cancer treatment

Safer. Faster. Complete.

Current molecular tests rely on invasive tumor biopsy procedures that put patients at risk and leave clinicians without timely information as cancer evolves. Even with a tissue biopsy, there may not be enough material for a molecular profile. In lung cancer, up to 25% of patients with locally advanced or metastatic NSCLC do not have tissue available for testing. We overcome these limitations by exploiting the fact that many solid tumors release DNA into the bloodstream. By taking a standard blood draw, a "liquid biopsy", we are able to provide a comprehensive genetic profile of a solid tumor.
  • Safely identify actionable mutations to guide therapy selection
  • Detect disease progression earlier
  • Monitor therapeutic efficacy over time
  • Characterize acquired drug resistance
  • Obtain a molecular estimate of tumor burden
  • Track tumor evolution

Our Platform

Our cell-free DNA platform integrates a novel molecular targeting system with proprietary bioinformatics methods to dramatically improve the detection capabilities of next-generation sequencing. This technology enables comprehensive analysis of all types of tumor-derived genomic alterations in an unbiased manner. We believe our platform is unique in identifying cancer driving gene fusions without any prior knowledge of the fusion partner or breakpoint. This ability to "discover" fusions is critical to providing a complete picture of a tumor's genetic profile. Our extremely efficient process allows us to profile several patient samples on a single desktop sequencing run — making our system not only comprehensive and fast, but practical for clinics.
Fusions • Amplifications • INDELS • BASE SUBSTITUTIONS


  • Diagnostics
  • Our inital product is a focused, actionable gene panel for non-small cell lung cancer (NSCLC). Collaborations show accurate detection of all four major types of mutations.

  • Research
  • We provide custom analysis and testing services to address a wide range of translational research and biomarker discovery applications.

  • Trials
  • We offer assay development and validation services to support clinical trials through our CLIA laboratory 2015.

About Us

Resolution Bioscience was founded in 2012 by leading experts in next generation sequencing, genomic analysis and commercial product development. Our mission is to transform cancer outcomes by providing physicians and pharmaceutical companies with noninvasive diagnostic tools to guide the development and clinical implementation of personalized treatment strategies.
  • Chris Raymond, PhD
  • Chief Scientific Officer
  • Chris is an expert in genome sequencing, with a track record of inventing important new techniques. Previously at NuGEN Technologies, he led an R&D team that created cutting edge sample preparation methods for next-generation sequencing. At Merck Research Laboratories, Chris invented novel assay technologies to measure global copy number variation in cancer genomes, microRNA dynamics in colorectal cancer and somatic mutations in clinical tumor biopsies. His intellectual property portfolio forms the basis of several products commercialized by major life science companies. Chris holds B.S. and Ph.D. degrees in Chemistry from the University of California at Santa Cruz and the University of Oregon.
  • Lee Lim, PhD
  • Chief Technology Officer
  • Lee is an expert in deciphering the complex biology behind genome sequences. His work has led to fundamental discoveries in RNA biology and has been featured in high profile papers published in leading scientific journals. At the Rosetta Inpharmatics and Sirna divisions of Merck Research Laboratories, Lee pioneered the use of microRNAs as plasma biomarkers, elucidated a microRNA component of the p53 tumor suppressor pathway, and developed microRNA mimics for anti-cancer therapeutic applications. He holds a bachelor’s degree from Stanford University and a Ph.D. from Massachusetts Institute of Technology. Lee is a recipient of the AAAS Newcomb Cleveland Prize.
  • Mark Li
  • Chief Executive Officer
  • Mark is an investor and serial entrepreneur. He pioneered early desktop publishing in the book, magazine and multimedia CD-ROM industry while at Ziff-Davis Publishing. He was part of the two-person startup team which founded Yahoo! Europe and was responsible for starting and overseeing engineering for regional Yahoo!s in 23 countries and languages. Since Yahoo!, Mark has started several companies in diverse locations and fields such as EU liquor distribution in Estonia and solar thermal monitoring in Seattle.